World Hemophilia Day:
Recognizing All Bleeding Disorders

Annually, April 17 marks "World Hemophilia Day," an international day established with the aim of increasing public awareness about hemophilia, fostering greater understanding and support for hemophilia patients and their families, and incentivizing research innovation to enhance the quality of life for those affected. The theme of the event this year is “Equitable access for all: recognizing all bleeding disorders”.

Hemophilia, an X-linked recessive genetic disorder primarily affecting males, is caused by a deficiency or dysfunction of clotting factors VIII or IX, with Hemophilia A (Factor VIII deficiency) and Hemophilia B (Factor IX deficiency) being the two main disease types. Due to the lack of these crucial clotting factors, the clotting process is impaired, rendering patients unable to effectively form clots to seal wounds. Hemophilia patients often exhibit an uncontrolled bleeding tendency, with even minor traumas or spontaneous bleeding episodes posing significant threats to their well-being, and potentially endangering their lives. While females typically serve as carriers, they may also manifest symptoms under certain circumstances. ( Learn more about Hemophilia >> )

Significant advancements have been made in hemophilia research in recent years. Scientists are actively exploring novel therapeutic approaches, including gene therapy, long-acting clotting factor replacement therapies, and small molecule drug development. Gene therapy stands out as one of the most exciting directions, with researchers striving to introduce normal clotting factor genes into patients' bodies via viral vectors, enabling them to produce sufficient clotting factors for long-term or even permanent therapeutic effects. Moreover, targeting other regulatory factors within the coagulation pathway for pharmaceutical intervention has emerged as a new focus in drug target exploration.

In drug development, several long-acting clotting factor products have already received market approval, capable of maintaining clotting factor levels in the blood for extended periods, reducing injection frequency, and significantly enhancing patients' quality of life. Concurrently, non-factor therapies, such as antisense oligonucleotide drugs and antibody-based therapies, demonstrate promising potential in clinical trials, poised to offer a more diverse array of treatment options in the future.

CUSABIO consistently dedicates itself to providing high-quality research reagents such as proteins, antibodies, and ELISA kits to researchers. Given the criticality and urgency of hemophilia research, we have specially curated a list of more than 20 popular targets and related reagent products pertinent to hemophilia studies below for your selection.